Recently, EY (United States) announced that Dr. Zhong Jing, Founder, Chairman, and CEO of HiFiBiO Therapeutics, a company within the Concora Place Campus, has been honored with the 2024 EY Entrepreneur Of The Year® Award in the New England region. The EY Entrepreneur Of The Year® Award is one of the most prestigious international business awards in the world, designed to highlight the outstanding contributions of entrepreneurs and their teams in areas such as new insights, leadership, and achievement.
All winners are selected by an independent judging panel composed of leaders and experts from the social and business communities, as well as past recipients of the EY Entrepreneur Of The Year® Award. The panel assesses the candidates’ ability to create long-term value based on key indicators such as their entrepreneurial spirit, commitment to their mission, significant growth, and impact of their company.
Dr. Zhong Jing, Founder, Chairman, and CEO of HiFiBiO Therapeutics, stated:
“I am delighted to be chosen for the EY Entrepreneur Of The Year® Award among so many outstanding entrepreneurs and business leaders. This honor is an affirmation of HiFiBiO Therapeutics’ highly innovative work in drug development. We are dedicated to developing industry-leading immunomodulatory bio-innovative drugs, harnessing groundbreaking immunotherapies to unlock the healing potential of every patient’s immune system, thereby improving patients’ lives. I am extremely honored to join the ranks of EY’s annual entrepreneurs, leading the industry’s development alongside other distinguished leaders.”
About the EY Entrepreneur Of The Year® Award: The EY Entrepreneur Of The Year® Award, first held in 1986, aims to recognize the originality, courage, and entrepreneurial spirit of many entrepreneurs. The award encourages different types of business leaders: founders of startups who build their companies from the ground up or raise funds to grow, transformative CEOs who inject innovation into existing organizations to drive their development, and family business leaders who change traditional models to consolidate the company’s trajectory. Today, the award has expanded to over 80 countries and regions, with more than 10,000 innovative outstanding entrepreneurs worldwide having the honor to participate in the selection process.
Past recipients of the EY Entrepreneur Of The Year® Award include business leaders such as:
• Hamdi Ulukaya, CEO and Founder of Chobani
• Howard Schultz, former Executive Chairman and CEO of Starbucks
• James Park, CEO of Fitbit
• Reid Hoffman and Jeff Weiner, Co-founder and Executive Chairman of LinkedIn, respectively
About HiFiBiO Therapeutics:
HiFiBiO Therapeutics is a clinical-stage biopharmaceutical company that has developed a pipeline of innovative immunotherapies targeting cancer and autoimmune diseases. This includes three drugs currently in Phase I clinical trials: a first-in-class agonist antibody targeting TNFR2, a best-in-class blocking antibody targeting BTLA, and a next-generation agonist antibody targeting OX40. Throughout the entire lifecycle of innovative drug development, HiFiBiO Therapeutics continuously utilizes its unique translational science platform, Drug Intelligence Science (DIS®), to deeply analyze the biological mechanisms of human diseases and accelerate the drug development process. This platform disruptively combines single-cell technology with artificial intelligence/machine learning to discover new drug targets, screen high-quality drug candidate molecules, and select the most appropriate indications and predictive biomarkers for drugs, thereby maximizing clinical success rates. HiFiBiO Therapeutics has always adhered to an open innovation strategy, reaching numerous collaborations with top pharmaceutical companies worldwide to seek breakthrough solutions for patients.
